PPH
VanEck Pharmaceutical ETF
PPH
VanEck Pharmaceutical ETF
PPH
VanEck Pharmaceutical ETF
PPH
VanEck Pharmaceutical ETF
-
NAV$90.03
as of December 04, 2024 -
YTD RETURNS12.25%
as of December 04, 2024 -
Total Net Assets$611.17M
as of December 04, 2024 -
Total Expense Ratio0.36%
-
Inception Date12/20/2011
Fund Description
VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.
Overview
Fund Highlights
- Highly Liquid Companies
Index seeks to track the most liquid companies in the industry based on market capitalization and trading volume
- Industry Leaders
Index methodology favors the largest companies in the industry
- Global Scope
Portfolio may include both domestic and U.S. listed foreign companies, allowing for enhanced industry representation
RECOMMENDED INSIGHTS
Diversified Exposure to the Weight Loss Drug Market
Diversified Exposure to the Weight Loss Drug Market